Alexander C Egbe1, William R Miranda2, C Charles Jain2, Heidi M Connolly2. 1. Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA. Electronic address: egbe.alexander@mayo.edu. 2. Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Abstract
OBJECTIVES: The purpose of this study was to determine the risk factors for and prognostic implications of progressive right ventricular systolic dysfunction (RVD) in adults with congenitally corrected transposition of great arteries. BACKGROUND: There are no effective therapies for RVD; hence the need to identify and modify risk factors for progressive RVD. METHODS: RV systolic function was assessed by using RV longitudinal strain (RV-LS). The first echocardiogram (baseline echocardiogram) and all subsequent annual echocardiograms performed within 5 years from the baseline echocardiogram were analyzed. Progressive RVD (temporal decline in RV-LS) was assessed as the average annual change in RV-LS within 5 years of imaging follow-up. RESULTS: Of 186 patients (mean age 40 ± 12 years), the RV-LS at baseline was -17% ± 4%, and the annual decline in RV-LS was -4% (95% CI: -6 to -2). The risk factors for progressive RVD were left ventricular (LV) systolic dysfunction, LV pacing, and systemic hypertension. Cardiovascular events (heart failure hospitalization, heart transplant, and death) occurred in 57 (27%) patients. Progressive RVD was associated with cardiovascular events, independent of RV systolic function at baseline. In subgroup analyses assessing impact of therapies (medical therapy, cardiac resynchronization therapy, and tricuspid valve replacement), only tricuspid valve replacement was associated with improvement in RV systolic function when performed before onset of RVD. CONCLUSIONS: Patients with congenitally corrected transposition of great arteries were at risk for progressive RVD, and the risk factors for progressive RVD were LV pacing, systemic hypertension, and concomitant LV dysfunction. Further studies are required to determine whether strict blood pressure control and early tricuspid valve replacement will prevent progressive RVD.
OBJECTIVES: The purpose of this study was to determine the risk factors for and prognostic implications of progressive right ventricular systolic dysfunction (RVD) in adults with congenitally corrected transposition of great arteries. BACKGROUND: There are no effective therapies for RVD; hence the need to identify and modify risk factors for progressive RVD. METHODS: RV systolic function was assessed by using RV longitudinal strain (RV-LS). The first echocardiogram (baseline echocardiogram) and all subsequent annual echocardiograms performed within 5 years from the baseline echocardiogram were analyzed. Progressive RVD (temporal decline in RV-LS) was assessed as the average annual change in RV-LS within 5 years of imaging follow-up. RESULTS: Of 186 patients (mean age 40 ± 12 years), the RV-LS at baseline was -17% ± 4%, and the annual decline in RV-LS was -4% (95% CI: -6 to -2). The risk factors for progressive RVD were left ventricular (LV) systolic dysfunction, LV pacing, and systemic hypertension. Cardiovascular events (heart failure hospitalization, heart transplant, and death) occurred in 57 (27%) patients. Progressive RVD was associated with cardiovascular events, independent of RV systolic function at baseline. In subgroup analyses assessing impact of therapies (medical therapy, cardiac resynchronization therapy, and tricuspid valve replacement), only tricuspid valve replacement was associated with improvement in RV systolic function when performed before onset of RVD. CONCLUSIONS: Patients with congenitally corrected transposition of great arteries were at risk for progressive RVD, and the risk factors for progressive RVD were LV pacing, systemic hypertension, and concomitant LV dysfunction. Further studies are required to determine whether strict blood pressure control and early tricuspid valve replacement will prevent progressive RVD.
Authors: Anne M Dubin; Jan Janousek; Edward Rhee; Margaret J Strieper; Frank Cecchin; Ian H Law; Kevin M Shannon; Joel Temple; Eric Rosenthal; Frank J Zimmerman; Andrew Davis; Peter P Karpawich; Amin Al Ahmad; Victoria L Vetter; Naomi J Kertesz; Maully Shah; Christopher Snyder; Elizabeth Stephenson; Mathias Emmel; Shubhayan Sanatani; Ronald Kanter; Anjan Batra; Kathryn K Collins Journal: J Am Coll Cardiol Date: 2005-12-20 Impact factor: 24.094
Authors: Gerhard-Paul Diller; Jelena Radojevic; Aleksander Kempny; Rafael Alonso-Gonzalez; Liodakis Emmanouil; Stefan Orwat; Lorna Swan; Anselm Uebing; Wei Li; Konstantinos Dimopoulos; Michael A Gatzoulis; Helmut Baumgartner Journal: Am Heart J Date: 2012-05 Impact factor: 4.749
Authors: T P Graham; Y D Bernard; B G Mellen; D Celermajer; H Baumgartner; F Cetta; H M Connolly; W R Davidson; M Dellborg; E Foster; W M Gersony; I H Gessner; R A Hurwitz; H Kaemmerer; J D Kugler; D J Murphy; J A Noonan; C Morris; J K Perloff; S P Sanders; J L Sutherland Journal: J Am Coll Cardiol Date: 2000-07 Impact factor: 24.094
Authors: T P Graham; M D Parrish; R J Boucek; R C Boerth; J A Breitweser; S Thompson; R M Robertson; J R Morgan; G C Friesinger Journal: Am J Cardiol Date: 1983-01-15 Impact factor: 2.778